Kymera ($KYMR) Reports Milestone in Phase 1 Trial for KT-621 STAT6 Degrader

Oct 25, 2024, 01:04 PM

Kymera Therapeutics has announced the dosing of the first participant in a Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader. KT-621 targets STAT6, a historically undrugged transcription factor in the IL-4/IL-13 signaling pathways, which is a central driver of T helper type 2 (TH2) inflammation in allergic diseases. The trial represents a significant milestone in the treatment of TH2 immuno-inflammatory diseases. KT-621 is designed to be taken once daily.